Contributions of human brain biochemical studies to movement disorders

Parkinsonism and Related Disorders

Volumn 8, Issue 6, 2002, Pages 425-431

  Rajput, Ali H ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; LEVODOPA; NORADRENALIN;

BRAIN FUNCTION; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFECT; DYSTONIA; ESSENTIAL TREMOR; HUMAN; MEDICAL RESEARCH; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BRAIN CHEMISTRY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MOVEMENT DISORDERS;

EID: 0036767647     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(02)00026-3     Document Type: Review

References (47)

1. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disorders. 4:1998;53-57.
2. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia - normal and in Parkinson's disease. J Chem Neuroanat. 22:2001;3-12.
3. Kish S.J., Shannak K., Rajput A., Deck J.H.N., Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem. 58:1992;642-648.
4. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in Akinesia, rigidity, chorea, and tremor. J Neurol Sci. 14:1971;427-455.
5. Hornykiewicz O. Levodopa in the 1960s: starting point Vienna. Poewe W., Lees A.J. 20 years of Madopar-New Avenues. 1994;11-27 Roche, Basel.
6. Sano H. Biochemistry of the extrapyramidal system. Parkinsonism Relat Disorders. 6:2000;3-6. English Translation.
7. Weber G. On brain cholinesterase content in cerebral tumours and in parkinsonism. Bull Schweiz Akad Med Wiss. 8:1952;263-268.
8. Montagu K.A. Catechol compounds in rat tissues and in brains of different animals. Nature. 180:1957;244-245.
9. Sano I., Gamo T., Kakimoto Y., Taniguchi K., Takesada M., Nishinuma K. Distribution of catechol compounds in human brain. Biochim Biophys Acta. 32:1959;586-587.
10. Bertler A., Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia. 15:1959;10-11.
11. Hornykiewicz O. How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago. Wiener Klinische Wochenschrift. 113/22:2001;855-862.
12. Foley P. The L-DOPA story revisited. Further surprises to be expected? J Neural Transm. 60:(Suppl):2000;1-20.
13. Hornykiewicz O. From dopamine to Parkinson's disease: a personal research record. Samson F., Adelman G. The neurosciences: paths of discovery. 2nd ed :1992;125-147 Birkhauser, Boston.
14. Brucke F. A propos de la synthese et du metabolisme des catecholamines. Revue Medicale ae Liege. 15:1960;505-512.
15. Birkmayer W., Hornykiewicz O. The effect of L-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Related Disorders. 4:1998;59-60. English Translation.
16. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of Parkinsonism. N Engl J Med. 276:1967;374-379.
17. Barolin G.S., Bernheimer H., Hornykiewicz O. Side differences in brain dopamine (3-hydroxytyramine) levels in a case with hemiparkinsonism. Schweiz Arch Neurol Neurochir Psychiatry. 94:1964;241-248.
18. Bernheimer H., Birkmayer W., Jellinger K., Seitelberger F., Hornykiewicz O. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci. 20:(4):1973;415-455.
19. Bernheimer H., Hornykiewicz O. Herabgesetzte Konzentration der Homovanillinsaure im Gehirn von Parkinsonkranken Menschen als Ausdruck der Storung des zentralen Dopaminstoffwechsels. KlinWochenschr. 43:1965;711-715.
20. Lloyd K.G., Hornykiewicz O. Occurrence and distribution of L-DOPA decarboxylase in the human brain. Brain Res. 22:1970;426-428.
21. Lloyd K., Hornykiewicz O. Parkinson's disease: activity of L-DOPA decarboxylase in discrete brain regions. Science. 170:1970;1212-1213.
22. Davidson L., Lloyd K.G., Dankova J., Hornykiewicz O. L-Dopa treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions. Experientia. 27:1971;1048-1049.
23. Lloyd K.G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 195:1975;453-464.
24. Rajput A.H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced Parkinsonism. Clinicopathologic study of two cases. Arch Neurol. 39:1982;644-646.
25. Farley I.J., Hornykiewicz O. Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects. Birkmayer W., Hornykiewicz O. Advances in parkinsonism. 1976;178-185 Roche, Basel.
26. Kish S.J., Shannak K.S., Rajput A.H., Gilbert J.J., Hornykiewicz O. Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch Neurol. 41:1984;612-614.
27. Lee T., Seeman P., Rajput A.H., Farley I.J., Hornykiewicz O. Receptor basis for dopeminergic supersensitivity in Parkinson's disease. Nature. 273:1978;59-61.
28. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med. 318:1988;876-880.
29. Sitte H., Fenton M.E., Pifl C., Rajput A.H., Hornykiewicz O. Globus Pallidus (GP) dopamine (DA) metabolism and Parkinson's disease (PD) manifestations. Neurology. 52:(Suppl. 2):1999;A213.
30. Tiraboschi P., Hansen L.A., Alford M. Cholinergic dysfucntion in diseases with Lewy bodies. Neurology. 54:2000;407-411.
31. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 17:(1):2002;60-67.
32. Rajput A.H., Fenton M.E., Birdi S., Macaulay R., George D., Rozdilsky B., Ang L.C., Senthilselvan A., Hornykiewciz O. A clinical-pathological study of Levodopa complications. Mov Disord. 2002;. in press.
33. Rajput A.H. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Related Disorders. 8:2001;95-100.
34. Rajput A.H., Fenton M., Sitte H., Pifl C., Hornykiewicz O. Brain dopamine (DA) metabolism in dyskinesia and wearing off in idiopathic Parkinson's disease (PD). Neurology. 50:1998;A392. Abstract.
35. Tekumalla P.K., Calon F., Rahman Z., Birdi S., Rajput A.H., Hornykiewicz O., DiPaolo T., Bedard P.J., Nestler E.J. Elevated levels of FosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry. 50:2001;813-816.
36. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo P.J. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp. 61:(2):2001;186-192.
37. Rajput A.H., Gibb W.R.G., Zhong X.H., et al. Dopa-responsive dystonia: pathological and biochemical observations in a case. Ann Neurol. 35:1994;396-402.
38. Louis E.D., Marder K., Cote L. Prevalence of a history of shaking in persons 65 years of age and older: diagnostic and functional correlates. Mov Disord. 11:1996;63-69.
39. Rajput A.H., Offord K.P., Beard C.M., Kurland L.T. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry. 47:1984;466-470.
40. Rajput A.H., Rozdilsky B., Ang L., Rajput A. Clinicopathological observations in essential tremor. Report of 6 cases. Neurology. 41:1991;1422-1424.
41. Rajput A.H., Rozdilsky B., Ang L., Rajput A. Significance of Parkinsonian manifestations in essential tremor. Can J Neurol Sci. 20:1993;114-117.
42. Rajput A.H. Pathological and neurochemical basis of essential tremor. Koller W.C., Findley L.J. Handbook of tremor disorders. 1994;233-244 Marcel Dekker, New York.
43. Rajput A.H., Hornykiewicz O., Deng Y., Birdi S., Miyashita H., Macaulay R. Increased noradrenaline levels in essential tremor brain. Neurology. 56:(Suppl. 3):2001;A302. Abstract.
44. 6. Klin Wochenschr. 38:1960;120-123.
45. Parkinsonism Relat Disorders. 7:2001;149-155.
46. Hornykiewicz O. Topography and behaviour of noradrenaline and dopamine (3-hydroxytyramine) in the substantia nigra of normal and Parkinsonian patients. Wiener Klinische Wochenschrift. 75:1963;309-312. in German.
47. Hornykiewicz O. The distribution and metabolism of catecholamines and 5-hydroxytryptamine in human brain. Richter D. Comparative neurochemistry. 1964;379-386 Pergamon Press, Oxford.